Nothing Special   »   [go: up one dir, main page]

BRPI0609121B8 - 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2 - Google Patents

1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2

Info

Publication number
BRPI0609121B8
BRPI0609121B8 BRPI0609121A BRPI0609121A BRPI0609121B8 BR PI0609121 B8 BRPI0609121 B8 BR PI0609121B8 BR PI0609121 A BRPI0609121 A BR PI0609121A BR PI0609121 A BRPI0609121 A BR PI0609121A BR PI0609121 B8 BRPI0609121 B8 BR PI0609121B8
Authority
BR
Brazil
Prior art keywords
benzimidazole
quaternary carbon
compounds
formula
parp
Prior art date
Application number
BRPI0609121A
Other languages
English (en)
Inventor
Zhu Guidong
Gong Jianchun
D Pennig Thomas
Giranda Vincent
B Gandhi Virajkumar
Original Assignee
Abbott Lab
Abbvie Bahamas Ltd
Abbvie Inc
Abbvie Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Abbvie Bahamas Ltd, Abbvie Inc, Abbvie Ireland Unlimited Co filed Critical Abbott Lab
Publication of BRPI0609121A2 publication Critical patent/BRPI0609121A2/pt
Publication of BRPI0609121B1 publication Critical patent/BRPI0609121B1/pt
Publication of BRPI0609121B8 publication Critical patent/BRPI0609121B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternario na posição 2 são potentes inibidores de parp. a presente invenção se refere a compostos de fórmula (i) que inibem a enzima parp e são úteis para o tratamento de uma doença ou de uma desordem associada à parp. também são descritas as composições farmacêuticas que compreendem os compostos de fórmula (i), métodos de tratamento compreendendo os compostos de fórmula (i), e os métodos de inibição da enzima parp compreendendo os compostos de fórmula (i).
BRPI0609121A 2005-04-11 2006-04-11 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2 BRPI0609121B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67020405P 2005-04-11 2005-04-11
US60/670.204 2005-04-11
PCT/US2006/013652 WO2006110816A2 (en) 2005-04-11 2006-04-11 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors

Publications (3)

Publication Number Publication Date
BRPI0609121A2 BRPI0609121A2 (pt) 2010-02-23
BRPI0609121B1 BRPI0609121B1 (pt) 2021-04-27
BRPI0609121B8 true BRPI0609121B8 (pt) 2021-05-25

Family

ID=36940094

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0609121A BRPI0609121B8 (pt) 2005-04-11 2006-04-11 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2

Country Status (24)

Country Link
US (1) US7550603B2 (pt)
EP (3) EP1869011B1 (pt)
JP (1) JP4960342B2 (pt)
KR (1) KR101349206B1 (pt)
CN (2) CN104961723A (pt)
AU (1) AU2006235492B2 (pt)
BR (1) BRPI0609121B8 (pt)
CA (1) CA2603784C (pt)
CY (1) CY1123919T1 (pt)
DK (2) DK1869011T3 (pt)
ES (2) ES2426981T3 (pt)
HK (3) HK1119168A1 (pt)
HR (2) HRP20120819T1 (pt)
IL (2) IL186303A (pt)
ME (2) ME02087B (pt)
MX (1) MX2007012593A (pt)
NZ (1) NZ561729A (pt)
PL (2) PL1869011T3 (pt)
PT (2) PT2420234E (pt)
RS (2) RS52990B (pt)
SI (1) SI2420234T1 (pt)
TW (1) TWI375673B (pt)
WO (1) WO2006110816A2 (pt)
ZA (1) ZA200904501B (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010100977A (ko) 1998-11-03 2001-11-14 스타르크, 카르크 치환된 2-페닐벤즈이미다졸, 그의 제조 및 그의 용도
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2006110683A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
JP2008543786A (ja) * 2005-06-10 2008-12-04 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ調節因子及び癌の治療
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
JP5227796B2 (ja) * 2005-09-29 2013-07-03 アボット・ラボラトリーズ ２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である
DE602006013191D1 (de) * 2005-11-15 2010-05-06 Abbott Lab Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
US20080293795A1 (en) * 2006-01-17 2008-11-27 Abbott Laboratories Combination therapy with parp inhibitors
US20090029966A1 (en) * 2006-01-17 2009-01-29 Abbott Laboratories Combination therapy with parp inhibitors
WO2007084532A2 (en) * 2006-01-17 2007-07-26 Abbott Laboratories Combination therapy with parp inhibitors
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
US20080280867A1 (en) * 2006-01-17 2008-11-13 Abbott Laboratories Combination therapy with parp inhibitors
CA2647545C (en) * 2006-04-03 2016-02-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
CN101511821B (zh) * 2006-05-02 2013-07-17 Abbvie公司 取代的1h-苯并咪唑-4-羧酰胺类化合物是有效的parp抑制剂
JP2010502731A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
EP2059498A4 (en) 2006-09-05 2011-01-12 Bipar Sciences Inc TREATMENT OF CANCER
US20100055071A1 (en) * 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
RS58936B1 (sr) * 2007-01-10 2019-08-30 Msd Italia Srl Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
US8242303B2 (en) * 2007-08-01 2012-08-14 Nagase & Co., Ltd. Method of producing optically active N-(halopropyl) amino acid derivative
US20090062268A1 (en) * 2007-08-27 2009-03-05 Lead Therapeutics, Inc. Novel inhibitors of poly(adp-ribose)polymerase (parp)
CN101821269B (zh) * 2007-10-12 2014-05-28 艾伯维巴哈马有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
BRPI0816221A8 (pt) 2007-10-12 2015-09-22 Abbott Lab forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
RU2480211C2 (ru) 2007-11-12 2013-04-27 Байпар Сайенсиз, Инк. Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами
US8436185B2 (en) * 2008-01-08 2013-05-07 Merck Sharp & Dohme Corp. Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
EP2247600A4 (en) * 2008-02-06 2011-09-14 Biomarin Pharm Inc BENZOXAZOLEBOXYLIC ACID AMIDE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP)
KR101007239B1 (ko) 2008-08-20 2011-01-13 한국화학연구원 2-설파닐-벤즈이미다졸-4-카르복스아미드 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(ａｄｐ-리보스)폴리머라제-1(ｐａｒｐ-1)의 과활성에 의해 유발되는 질환의 예방 또는 치료용 약학적 조성물
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
CA2798697A1 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
US20120258180A1 (en) * 2011-04-11 2012-10-11 Abbott Laboratories Parp inhibitors for the treatment of cipn
JP5964297B2 (ja) 2011-05-31 2016-08-03 株式会社エーピーアイ コーポレーション 光学活性α−置換プロリン類の製造方法
WO2013011999A1 (ja) 2011-07-20 2013-01-24 株式会社カネカ 光学活性２－メチルプロリン誘導体の製造法
CA2873119A1 (en) 2012-05-15 2013-11-21 Abbvie Inc. Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
US9346743B2 (en) 2012-10-15 2016-05-24 Albemarle Corporation Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds
WO2014153529A1 (en) 2013-03-22 2014-09-25 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
EP3004086A1 (de) 2013-06-03 2016-04-13 Bayer Pharma Aktiengesellschaft Substituierte benzoxazole
CN104230898B (zh) * 2013-06-17 2016-06-29 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN104230897B (zh) * 2013-06-17 2016-07-06 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
EP3079690A1 (en) 2013-12-10 2016-10-19 AbbVie Inc. Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
CN104926793B (zh) * 2014-03-21 2017-05-24 成都海创药业有限公司 一种治疗肿瘤的化合物及其用途
MX2016016115A (es) 2014-06-17 2017-03-08 Vertex Pharma Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
CN106317069A (zh) * 2015-06-26 2017-01-11 中国科学院上海药物研究所 2-取代苯并咪唑-4-甲酰胺类化合物及制备方法和应用
ES2742197T7 (es) 2015-07-23 2021-10-06 Inst Curie Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106432195B (zh) * 2015-08-12 2020-01-14 杭州民生药物研究院有限公司 一种制备(r)-2-(2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺的方法
MX2018001659A (es) 2015-08-20 2018-05-28 Ipsen Biopharm Ltd Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
PT3337478T (pt) 2015-08-21 2020-10-19 Ipsen Biopharm Ltd Combinação de fármacos compreendendo irinotecano lipossómico, oxaliplatina, 5-fluorouracilo e leucovorina para o tratamento do cancro do pâncreas metastático
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
US20190092756A1 (en) * 2016-03-09 2019-03-28 Crystal Pharmatech Co., Ltd. Crystalline form a of 2-[(2r)-2-methyl-2-pyrrolidyl]-1h-benzimidazole-7-carboxamide dihydrochloride and preparation method thereof
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
CN107200704A (zh) * 2016-03-18 2017-09-26 罗欣生物科技（上海）有限公司 一种维利帕尼的中间体晶体及其制备方法
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form
EA201990979A1 (ru) 2016-11-02 2019-09-30 Ипсен Биофарм Лтд. Способы лечения рака желудочно-кишечного тракта с применением комбинационных видов терапии, содержащих липосомальный иринотекан и оксалиплатин
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN107098849B (zh) * 2017-04-11 2019-09-20 山东百诺医药股份有限公司 一种盐酸左布比卡因的制备方法
CN106866501B (zh) * 2017-04-11 2019-09-20 山东百诺医药股份有限公司 一种盐酸左布比卡因的制备方法
CA3021507A1 (en) 2017-10-24 2019-04-24 Apotex Inc. Processes for the preparation of veliparib and intermediates thereof
CA3127990A1 (en) * 2018-01-30 2019-08-08 Board Of Regents, The University Of Texas System Pipecolic esters for inhibition of the proteasome
JP7534218B2 (ja) 2018-03-13 2024-08-14 ヴァレリオ・セラピューティクス がんの治療における獲得耐性に対抗するｄｂａｉｔ分子
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111471039B (zh) * 2020-05-20 2023-07-25 上海腾卓药业有限责任公司 维利帕尼的制备方法
WO2024057249A1 (en) * 2022-09-14 2024-03-21 Zydus Lifesciences Limited Improved process for the preparation of sulfonylurea based compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1021468B (de) * 1954-09-15 1957-12-27 Heinrich Hermanns Traenkeinrichtung fuer elektrische Wicklungen, insbesondere fuer gewickelte Anker elektrischer Maschinen
GB1354554A (en) 1970-08-31 1974-06-05 Robins Co Inc A H 2-substituted benzimidazoles
BE789679A (fr) 1971-10-05 1973-04-04 Leo Pharm Prod Ltd Nouveaux derives d'acide amino-5 isophtalique et leurs procedesde preparation
US4093726A (en) 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
DE3522230A1 (de) 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP2562953B2 (ja) * 1988-09-02 1996-12-11 シルバー株式会社 燃焼器具用芯の耐熱部材
DE3830060A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
BR9610051A (pt) 1995-08-02 1999-12-21 Univ Newcastle Ventures Ltd Uso de um composto, processo de preparação do mesmo, formulação ou composição farmacêutica contendo um composto, composição farmacêutica, e, processo de tratamento terapeutico
PT970095E (pt) 1997-03-07 2004-03-31 Metabasis Therapeutics Inc Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
GB9815880D0 (en) 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
KR20010100977A (ko) 1998-11-03 2001-11-14 스타르크, 카르크 치환된 2-페닐벤즈이미다졸, 그의 제조 및 그의 용도
KR20010080474A (ko) 1998-11-17 2001-08-22 스타르크, 카르크 2-페닐벤즈이미다졸 및 2-페닐인돌, 이들의 제법 및 용도
DE19916460B4 (de) 1999-04-12 2006-12-21 Abbott Gmbh & Co. Kg Substituierte Benzimidazole, deren Herstellung und Anwendung
HUP0200749A3 (en) * 1998-11-27 2003-03-28 Basf Ag Substituted benzimidazoles and their use as parp inhibitors and process for their preparation
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
DE10021468A1 (de) 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
JPWO2002068407A1 (ja) 2001-02-28 2004-06-24 山之内製薬株式会社 ベンゾイミダゾール化合物
US7166292B2 (en) 2001-06-29 2007-01-23 The Procter & Gamble Company Top-biased beneficial components on substrates
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
EP1511744A4 (en) 2002-05-13 2009-10-21 Icagen Inc Bis-benzimidazoles and related compounds as potassium channel modulators
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
US20060084682A1 (en) 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
US7179832B2 (en) 2003-01-23 2007-02-20 Crystalgenomics, Inc. Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof
HU0301154D0 (en) * 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors

Also Published As

Publication number Publication date
MX2007012593A (es) 2007-11-16
PL1869011T3 (pl) 2013-01-31
NZ561729A (en) 2010-12-24
HRP20120819T1 (hr) 2012-11-30
WO2006110816A2 (en) 2006-10-19
EP2420234A1 (en) 2012-02-22
ES2426981T3 (es) 2013-10-28
ES2391832T3 (es) 2012-11-30
TWI375673B (en) 2012-11-01
CA2603784C (en) 2011-02-08
TW200720268A (en) 2007-06-01
BRPI0609121A2 (pt) 2010-02-23
HK1215807A1 (zh) 2016-09-15
CA2603784A1 (en) 2006-10-19
WO2006110816A3 (en) 2007-01-04
KR101349206B1 (ko) 2014-01-09
DK1869011T3 (da) 2012-11-12
ME02027B (me) 2013-04-30
IL186303A (en) 2013-07-31
KR20070120593A (ko) 2007-12-24
IL226619A0 (en) 2013-06-27
PT1869011E (pt) 2012-10-25
JP2008535926A (ja) 2008-09-04
ME02087B (me) 2014-02-28
PT2420234E (pt) 2013-10-08
CY1123919T1 (el) 2022-05-27
EP2420234B1 (en) 2013-07-10
IL186303A0 (en) 2008-01-20
SI2420234T1 (sl) 2013-10-30
DK2420234T3 (da) 2013-10-21
CN101155797A (zh) 2008-04-02
EP1869011B1 (en) 2012-08-01
AU2006235492A1 (en) 2006-10-19
ZA200904501B (en) 2010-05-26
US20060229289A1 (en) 2006-10-12
HK1119168A1 (en) 2009-02-27
RS52546B (en) 2013-04-30
US7550603B2 (en) 2009-06-23
HK1166465A1 (en) 2012-11-02
PL2420234T3 (pl) 2013-12-31
RS52990B (en) 2014-02-28
BRPI0609121B1 (pt) 2021-04-27
CN101155797B (zh) 2015-04-29
IL226619A (en) 2016-10-31
EP2420499B1 (en) 2013-07-10
CN104961723A (zh) 2015-10-07
EP2420499A1 (en) 2012-02-22
EP1869011A2 (en) 2007-12-26
JP4960342B2 (ja) 2012-06-27
HRP20130861T1 (hr) 2013-10-25
AU2006235492B2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
BRPI0810719A8 (pt) Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1
MX2007015863A (es) Inhibidores de esfingosina cinasa.
BRPI0607308A2 (pt) compostos, composições farmacêuticas e usos dos referidos compostos
DOP2006000149A (es) Derivados de isoquinolina
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
ECSP088136A (es) Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa
ECSP099467A (es) Derivados de isoquinolona sustituidos con cicloalquilamina
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
CR20110016A (es) Compuestos quimicos 251
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
BRPI0619153B8 (pt) derivados de 4-amino-pirroltriazina substituída, e composição farmacêutica
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
BRPI0916235B8 (pt) composto, composição farmacêutica, e, uso do composto ou da composição
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
UY29697A1 (es) Derivados de isoquinolona sustituidos con piperidinilo
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B25A Requested transfer of rights approved

Owner name: ABBVIE BAHAMAS LTD. (US)

B25A Requested transfer of rights approved

Owner name: ABBVIE IRELAND UNLIMITED COMPANY (BM)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09S Decision of refusal: publication cancelled [chapter 9.2.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 9.2 NA RPI NO 2517 DE 02/04/2019 POR TER SIDO INDEVIDA.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/04/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/04/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2718 DE 07-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.